Oliver Bruhn

OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications

Ruwen Böhm, Leocadie von Hehn, Thomas Herdegen et al. · PLoS ONE · 2016 · 236 citations · Full text

Drug Safety, Drug Interactions, Health Policy +13

MicroRNA profiling in K-562 cells under imatinib treatment

Eleonora Turrini, Sierk Haenisch, Sandra Laechelt et al. · Pharmacogenetics and Genomics · 2012 · 82 citations

Down-Regulation of ATP-Binding Cassette C2 Protein Expression in HepG2 Cells after Rifampicin Treatment Is Mediated by MicroRNA-379

Sierk Haenisch, Sandra Laechelt, Henrike Bruckmueller et al. · Molecular Pharmacology · 2011 · 79 citations

Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)

Anne T. Nies, Elke Schaeffeler, Heiko van der Kuip et al. · Clinical Cancer Research · 2013 · 60 citations · Full text

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Theresa Klümper, Henrike Bruckmueller, Tobias Diewock et al. · Experimental Hematology and Oncology · 2020 · 36 citations · Full text